Evommune (EVMN) Cash from Operations (2024 - 2026)
Evommune (EVMN) reported Cash from Operations of 27503000.0 for Q1 2026, down 15.08% year-over-year from 32387001.58 in Q1 2025, and down 64.7% quarter-over-quarter from 16699000.0 in Q4 2025.
Evommune (EVMN) Cash from Operations (2024 - 2026) Analysis & Trends
Evommune (EVMN) has 3 years of Cash from Operations data on file, last reported at 27503000.0 in Q1 2026.
- Cash from Operations for Q1 2026 came in at 27503000.0, down 15.08% year-over-year; the trailing twelve-month figure through Mar 2026 was 86613000.0 (changed N/A YoY), and the FY2025 annual result was 76441000.0, down 31.35% from the prior year.
- Cash from Operations retreated to 27503000.0 in Q1 2026 per EVMN's latest filing, from 16699000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 16699000.0 in Q4 2025 and troughed at 27503000.0 in Q1 2026.
- A 3-year average of 21653250.0 and a median of 21205500.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2025 and 2026: Cash from Operations increased 9.79% in 2025, then declined 15.08% in 2026.
- A 3-year view of Cash from Operations shows it stood at 18512000.0 in 2024, then rose by 9.79% to 16699000.0 in 2025, then plunged by 64.7% to 27503000.0 in 2026.
- Business Quant data shows EVMN's Cash from Operations at 27503000.0 in Q1 2026, 16699000.0 in Q4 2025, and 23899000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Evommune | 695.29 Mn | 483.82 Mn | - | -27.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.50 Mn |
| Mar 31, 2026 | -27.50 Mn |
| Dec 31, 2025 | -16.70 Mn |
| Dec 31, 2025 | -16.70 Mn |
| Mar 31, 2025 | -23.90 Mn |
| Mar 31, 2025 | -23.90 Mn |
| Dec 31, 2024 | -18.51 Mn |
| Dec 31, 2024 | -18.51 Mn |